{"entity":{"type":"insider","cik":"0001537670","url":"/insider/0001537670","json_url":"/insider/0001537670.json","name":"Holmes Scott A","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":25,"n_filings":23,"first":"2012-09-13","last":"2018-11-16","span_basis":"filed_date"},"name_variants":[{"name":"Holmes Scott A","source":"filing","n_filings":23,"first_seen":"2012-09-13","last_seen":"2018-11-16"}],"transactions":[{"id":6751585,"accession":"0001114220-18-000109","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001114220-18-000109","line_url":"/filing/0001114220-18-000109#line-1","is_derivative":false,"issuer_cik":"0001114220","issuer_name":"KERYX BIOPHARMACEUTICALS INC","issuer_ticker":"KERX","issuer_name_source":null,"issuer_url":"/issuer/0001114220","owner_cik":"0001537670","owner_name":"Holmes Scott A","owner_display_name":"Holmes Scott A","owner_url":"/insider/0001537670","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1155.0,"shares_display":"1,155","price_per_share":2.77,"price_display":"2.77","price_state":"stated","total_value":3199.35,"total_display":"3,199.35","total_whole":"3,199","shares_owned_after":162956.0,"shares_owned_after_display":"162,956","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-11-15","filed_date":"2018-11-16","scope":"insider"},{"id":6520556,"accession":"0001114220-18-000099","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001114220-18-000099","line_url":"/filing/0001114220-18-000099#line-1","is_derivative":false,"issuer_cik":"0001114220","issuer_name":"KERYX BIOPHARMACEUTICALS INC","issuer_ticker":"KERX","issuer_name_source":null,"issuer_url":"/issuer/0001114220","owner_cik":"0001537670","owner_name":"Holmes Scott A","owner_display_name":"Holmes Scott A","owner_url":"/insider/0001537670","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1254.0,"shares_display":"1,254","price_per_share":3.07,"price_display":"3.07","price_state":"stated","total_value":3849.78,"total_display":"3,849.78","total_whole":"3,850","shares_owned_after":164111.0,"shares_owned_after_display":"164,111","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-10-29","filed_date":"2018-10-30","scope":"insider"},{"id":6520553,"accession":"0001114220-18-000094","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001114220-18-000094","line_url":"/filing/0001114220-18-000094#line-1","is_derivative":false,"issuer_cik":"0001114220","issuer_name":"KERYX BIOPHARMACEUTICALS INC","issuer_ticker":"KERX","issuer_name_source":null,"issuer_url":"/issuer/0001114220","owner_cik":"0001537670","owner_name":"Holmes Scott A","owner_display_name":"Holmes Scott A","owner_url":"/insider/0001537670","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1185.0,"shares_display":"1,185","price_per_share":3.04,"price_display":"3.04","price_state":"stated","total_value":3602.4,"total_display":"3,602.40","total_whole":"3,602","shares_owned_after":165365.0,"shares_owned_after_display":"165,365","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-08-15","filed_date":"2018-08-16","scope":"insider"},{"id":6605784,"accession":"0001114220-18-000085","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001114220-18-000085","line_url":"/filing/0001114220-18-000085#line-1","is_derivative":false,"issuer_cik":"0001114220","issuer_name":"KERYX BIOPHARMACEUTICALS INC","issuer_ticker":"KERX","issuer_name_source":null,"issuer_url":"/issuer/0001114220","owner_cik":"0001537670","owner_name":"Holmes Scott A","owner_display_name":"Holmes Scott A","owner_url":"/insider/0001537670","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2354.0,"shares_display":"2,354","price_per_share":3.86,"price_display":"3.86","price_state":"stated","total_value":9086.44,"total_display":"9,086.44","total_whole":"9,086","shares_owned_after":166550.0,"shares_owned_after_display":"166,550","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-07-30","filed_date":"2018-07-31","scope":"insider"},{"id":6069561,"accession":"0001114220-18-000056","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001114220-18-000056","line_url":"/filing/0001114220-18-000056#line-1","is_derivative":false,"issuer_cik":"0001114220","issuer_name":"KERYX BIOPHARMACEUTICALS INC","issuer_ticker":"KERX","issuer_name_source":null,"issuer_url":"/issuer/0001114220","owner_cik":"0001537670","owner_name":"Holmes Scott A","owner_display_name":"Holmes Scott A","owner_url":"/insider/0001537670","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1158.0,"shares_display":"1,158","price_per_share":5.69,"price_display":"5.69","price_state":"stated","total_value":6589.02,"total_display":"6,589.02","total_whole":"6,589","shares_owned_after":168904.0,"shares_owned_after_display":"168,904","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-05-15","filed_date":"2018-05-16","scope":"insider"},{"id":6751581,"accession":"0001114220-18-000047","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001114220-18-000047","line_url":"/filing/0001114220-18-000047#line-1","is_derivative":false,"issuer_cik":"0001114220","issuer_name":"KERYX BIOPHARMACEUTICALS INC","issuer_ticker":"KERX","issuer_name_source":null,"issuer_url":"/issuer/0001114220","owner_cik":"0001537670","owner_name":"Holmes Scott A","owner_display_name":"Holmes Scott A","owner_url":"/insider/0001537670","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2407.0,"shares_display":"2,407","price_per_share":4.67,"price_display":"4.67","price_state":"stated","total_value":11240.69,"total_display":"11,240.69","total_whole":"11,241","shares_owned_after":170062.0,"shares_owned_after_display":"170,062","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-04-30","filed_date":"2018-05-01","scope":"insider"},{"id":6221409,"accession":"0001114220-18-000024","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001114220-18-000024","line_url":"/filing/0001114220-18-000024#line-1","is_derivative":false,"issuer_cik":"0001114220","issuer_name":"KERYX BIOPHARMACEUTICALS INC","issuer_ticker":"KERX","issuer_name_source":null,"issuer_url":"/issuer/0001114220","owner_cik":"0001537670","owner_name":"Holmes Scott A","owner_display_name":"Holmes Scott A","owner_url":"/insider/0001537670","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5651.0,"shares_display":"5,651","price_per_share":4.81,"price_display":"4.81","price_state":"stated","total_value":27181.31,"total_display":"27,181.31","total_whole":"27,181","shares_owned_after":131219.0,"shares_owned_after_display":"131,219","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-02-15","filed_date":"2018-02-16","scope":"insider"},{"id":6221400,"accession":"0001114220-18-000015","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001114220-18-000015","line_url":"/filing/0001114220-18-000015#line-1","is_derivative":false,"issuer_cik":"0001114220","issuer_name":"KERYX BIOPHARMACEUTICALS INC","issuer_ticker":"KERX","issuer_name_source":null,"issuer_url":"/issuer/0001114220","owner_cik":"0001537670","owner_name":"Holmes Scott A","owner_display_name":"Holmes Scott A","owner_url":"/insider/0001537670","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2830.0,"shares_display":"2,830","price_per_share":4.81,"price_display":"4.81","price_state":"stated","total_value":13612.3,"total_display":"13,612.30","total_whole":"13,612","shares_owned_after":136870.0,"shares_owned_after_display":"136,870","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-01-29","filed_date":"2018-01-31","scope":"insider"},{"id":5130051,"accession":"0001114220-17-000041","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001114220-17-000041","line_url":"/filing/0001114220-17-000041#line-1","is_derivative":false,"issuer_cik":"0001114220","issuer_name":"KERYX BIOPHARMACEUTICALS INC","issuer_ticker":"KERX","issuer_name_source":null,"issuer_url":"/issuer/0001114220","owner_cik":"0001537670","owner_name":"Holmes Scott A","owner_display_name":"Holmes Scott A","owner_url":"/insider/0001537670","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2582.0,"shares_display":"2,582","price_per_share":6.03,"price_display":"6.03","price_state":"stated","total_value":15569.46,"total_display":"15,569.46","total_whole":"15,569","shares_owned_after":139700.0,"shares_owned_after_display":"139,700","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-10-30","filed_date":"2017-10-31","scope":"insider"},{"id":5167893,"accession":"0001114220-17-000022","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001114220-17-000022","line_url":"/filing/0001114220-17-000022#line-1","is_derivative":false,"issuer_cik":"0001114220","issuer_name":"KERYX BIOPHARMACEUTICALS INC","issuer_ticker":"KERX","issuer_name_source":null,"issuer_url":"/issuer/0001114220","owner_cik":"0001537670","owner_name":"Holmes Scott A","owner_display_name":"Holmes Scott A","owner_url":"/insider/0001537670","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1445.0,"shares_display":"1,445","price_per_share":7.14,"price_display":"7.14","price_state":"stated","total_value":10317.3,"total_display":"10,317.30","total_whole":"10,317","shares_owned_after":142282.0,"shares_owned_after_display":"142,282","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-07-31","filed_date":"2017-08-01","scope":"insider"},{"id":5211651,"accession":"0001114220-17-000018","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001114220-17-000018","line_url":"/filing/0001114220-17-000018#line-1","is_derivative":false,"issuer_cik":"0001114220","issuer_name":"KERYX BIOPHARMACEUTICALS INC","issuer_ticker":"KERX","issuer_name_source":null,"issuer_url":"/issuer/0001114220","owner_cik":"0001537670","owner_name":"Holmes Scott A","owner_display_name":"Holmes Scott A","owner_url":"/insider/0001537670","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1236.0,"shares_display":"1,236","price_per_share":6.96,"price_display":"6.96","price_state":"stated","total_value":8602.56,"total_display":"8,602.56","total_whole":"8,603","shares_owned_after":143727.0,"shares_owned_after_display":"143,727","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-07-28","filed_date":"2017-07-31","scope":"insider"},{"id":4391043,"accession":"0000899243-17-011611","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-17-011611","line_url":"/filing/0000899243-17-011611#line-1","is_derivative":false,"issuer_cik":"0001114220","issuer_name":"KERYX BIOPHARMACEUTICALS INC","issuer_ticker":"KERX","issuer_name_source":null,"issuer_url":"/issuer/0001114220","owner_cik":"0001537670","owner_name":"Holmes Scott A","owner_display_name":"Holmes Scott A","owner_url":"/insider/0001537670","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1441.0,"shares_display":"1,441","price_per_share":5.97,"price_display":"5.97","price_state":"stated","total_value":8602.77,"total_display":"8,602.77","total_whole":"8,603","shares_owned_after":144963.0,"shares_owned_after_display":"144,963","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-05-01","filed_date":"2017-05-03","scope":"insider"},{"id":4138386,"accession":"0000899243-17-011264","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-17-011264","line_url":"/filing/0000899243-17-011264#line-1","is_derivative":false,"issuer_cik":"0001114220","issuer_name":"KERYX BIOPHARMACEUTICALS INC","issuer_ticker":"KERX","issuer_name_source":null,"issuer_url":"/issuer/0001114220","owner_cik":"0001537670","owner_name":"Holmes Scott A","owner_display_name":"Holmes Scott A","owner_url":"/insider/0001537670","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1219.0,"shares_display":"1,219","price_per_share":5.89,"price_display":"5.89","price_state":"stated","total_value":7179.91,"total_display":"7,179.91","total_whole":"7,180","shares_owned_after":146404.0,"shares_owned_after_display":"146,404","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-04-28","filed_date":"2017-05-01","scope":"insider"},{"id":4728259,"accession":"0000899243-17-002274","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-17-002274","line_url":"/filing/0000899243-17-002274#line-1","is_derivative":false,"issuer_cik":"0001114220","issuer_name":"KERYX BIOPHARMACEUTICALS INC","issuer_ticker":"KERX","issuer_name_source":null,"issuer_url":"/issuer/0001114220","owner_cik":"0001537670","owner_name":"Holmes Scott A","owner_display_name":"Holmes Scott A","owner_url":"/insider/0001537670","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8447.0,"shares_display":"8,447","price_per_share":4.65,"price_display":"4.65","price_state":"stated","total_value":39278.55,"total_display":"39,278.55","total_whole":"39,279","shares_owned_after":98873.0,"shares_owned_after_display":"98,873","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-01-30","filed_date":"2017-01-31","scope":"insider"},{"id":3240716,"accession":"0000899243-16-032475","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-16-032475","line_url":"/filing/0000899243-16-032475#line-1","is_derivative":false,"issuer_cik":"0001114220","issuer_name":"KERYX BIOPHARMACEUTICALS INC","issuer_ticker":"KERX","issuer_name_source":null,"issuer_url":"/issuer/0001114220","owner_cik":"0001537670","owner_name":"Holmes Scott A","owner_display_name":"Holmes Scott A","owner_url":"/insider/0001537670","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1237.0,"shares_display":"1,237","price_per_share":4.44,"price_display":"4.44","price_state":"stated","total_value":5492.28,"total_display":"5,492.28","total_whole":"5,492","shares_owned_after":107320.0,"shares_owned_after_display":"107,320","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-10-28","filed_date":"2016-10-31","scope":"insider"},{"id":2161131,"accession":"0000899243-16-026126","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-16-026126","line_url":"/filing/0000899243-16-026126#line-1","is_derivative":false,"issuer_cik":"0001114220","issuer_name":"KERYX BIOPHARMACEUTICALS INC","issuer_ticker":"KERX","issuer_name_source":null,"issuer_url":"/issuer/0001114220","owner_cik":"0001537670","owner_name":"Holmes Scott A","owner_display_name":"Holmes Scott A","owner_url":"/insider/0001537670","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4935.0,"shares_display":"4,935","price_per_share":7.36,"price_display":"7.36","price_state":"stated","total_value":36321.6,"total_display":"36,321.60","total_whole":"36,322","shares_owned_after":108557.0,"shares_owned_after_display":"108,557","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-07-29","filed_date":"2016-08-02","scope":"insider"},{"id":8653432,"accession":"0000899243-15-007649","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-15-007649","line_url":"/filing/0000899243-15-007649#line-2","is_derivative":false,"issuer_cik":"0001114220","issuer_name":"KERYX BIOPHARMACEUTICALS INC","issuer_ticker":"KERX","issuer_name_source":null,"issuer_url":"/issuer/0001114220","owner_cik":"0001537670","owner_name":"Holmes Scott A","owner_display_name":"Holmes Scott A","owner_url":"/insider/0001537670","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1328.0,"shares_display":"1,328","price_per_share":5.4,"price_display":"5.40","price_state":"stated","total_value":7171.2,"total_display":"7,171.20","total_whole":"7,171","shares_owned_after":59742.0,"shares_owned_after_display":"59,742","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-11-04","filed_date":"2015-11-05","scope":"insider"},{"id":8653430,"accession":"0000899243-15-007649","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-15-007649","line_url":"/filing/0000899243-15-007649#line-1","is_derivative":false,"issuer_cik":"0001114220","issuer_name":"KERYX BIOPHARMACEUTICALS INC","issuer_ticker":"KERX","issuer_name_source":null,"issuer_url":"/issuer/0001114220","owner_cik":"0001537670","owner_name":"Holmes Scott A","owner_display_name":"Holmes Scott A","owner_url":"/insider/0001537670","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3672.0,"shares_display":"3,672","price_per_share":5.299,"price_display":"5.30","price_state":"stated","total_value":19457.928,"total_display":"19,457.93","total_whole":"19,458","shares_owned_after":58414.0,"shares_owned_after_display":"58,414","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-11-03","filed_date":"2015-11-05","scope":"insider"},{"id":8316320,"accession":"0000899243-15-003909","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-15-003909","line_url":"/filing/0000899243-15-003909#line-1","is_derivative":false,"issuer_cik":"0001114220","issuer_name":"KERYX BIOPHARMACEUTICALS INC","issuer_ticker":"KERX","issuer_name_source":null,"issuer_url":"/issuer/0001114220","owner_cik":"0001537670","owner_name":"Holmes Scott A","owner_display_name":"Holmes Scott A","owner_url":"/insider/0001537670","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5000.0,"shares_display":"5,000","price_per_share":5.718,"price_display":"5.72","price_state":"stated","total_value":28590.0,"total_display":"28,590.00","total_whole":"28,590","shares_owned_after":54742.0,"shares_owned_after_display":"54,742","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-08-21","filed_date":"2015-08-24","scope":"insider"},{"id":8233866,"accession":"0000899243-15-002134","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-15-002134","line_url":"/filing/0000899243-15-002134#line-1","is_derivative":false,"issuer_cik":"0001114220","issuer_name":"KERYX BIOPHARMACEUTICALS INC","issuer_ticker":"KERX","issuer_name_source":null,"issuer_url":"/issuer/0001114220","owner_cik":"0001537670","owner_name":"Holmes Scott A","owner_display_name":"Holmes Scott A","owner_url":"/insider/0001537670","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2758.0,"shares_display":"2,758","price_per_share":7.87,"price_display":"7.87","price_state":"stated","total_value":21705.46,"total_display":"21,705.46","total_whole":"21,705","shares_owned_after":49742.0,"shares_owned_after_display":"49,742","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-07-31","filed_date":"2015-08-03","scope":"insider"},{"id":8235078,"accession":"0001179110-15-009972","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001179110-15-009972","line_url":"/filing/0001179110-15-009972","is_derivative":false,"issuer_cik":"0000792977","issuer_name":"AMAG PHARMACEUTICALS INC.","issuer_ticker":"AMAG","issuer_name_source":null,"issuer_url":"/issuer/0000792977","owner_cik":"0001537670","owner_name":"Holmes Scott A","owner_display_name":"Holmes Scott A","owner_url":"/insider/0001537670","role":"Officer (SVP, Finance and Treasurer)","role_mark":"O","role_mark_label":"Officer (SVP, Finance and Treasurer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Finance and Treasurer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7580.0,"shares_display":"7,580","price_per_share":66.63,"price_display":"66.63","price_state":"stated","total_value":505055.4,"total_display":"505,055.40","total_whole":"505,055","shares_owned_after":51958.0,"shares_owned_after_display":"51,958","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-06-15","filed_date":"2015-06-17","scope":"insider","n_lines":2},{"id":8895872,"accession":"0001179110-15-009261","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001179110-15-009261","line_url":"/filing/0001179110-15-009261#line-1","is_derivative":false,"issuer_cik":"0000792977","issuer_name":"AMAG PHARMACEUTICALS INC.","issuer_ticker":"AMAG","issuer_name_source":null,"issuer_url":"/issuer/0000792977","owner_cik":"0001537670","owner_name":"Holmes Scott A","owner_display_name":"Holmes Scott A","owner_url":"/insider/0001537670","role":"Officer (SVP, Finance and Treasurer)","role_mark":"O","role_mark_label":"Officer (SVP, Finance and Treasurer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Finance and Treasurer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":22516.0,"shares_display":"22,516","price_per_share":68.88,"price_display":"68.88","price_state":"stated","total_value":1550902.08,"total_display":"1,550,902.08","total_whole":"1,550,902","shares_owned_after":30788.0,"shares_owned_after_display":"30,788","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-06-03","filed_date":"2015-06-05","scope":"insider"},{"id":3346267,"accession":"0001242616-12-000021","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001242616-12-000021","line_url":"/filing/0001242616-12-000021#line-2","is_derivative":false,"issuer_cik":"0000792977","issuer_name":"AMAG PHARMACEUTICALS INC.","issuer_ticker":"AMAG","issuer_name_source":null,"issuer_url":"/issuer/0000792977","owner_cik":"0001537670","owner_name":"Holmes Scott A","owner_display_name":"Holmes Scott A","owner_url":"/insider/0001537670","role":"Officer (Chief Accounting Officer)","role_mark":"O","role_mark_label":"Officer (Chief Accounting Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Accounting Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2500.0,"shares_display":"2,500","price_per_share":14.79,"price_display":"14.79","price_state":"stated","total_value":36975.0,"total_display":"36,975.00","total_whole":"36,975","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-12-05","filed_date":"2012-12-06","scope":"insider"},{"id":2616940,"accession":"0001242616-12-000019","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001242616-12-000019","line_url":"/filing/0001242616-12-000019#line-2","is_derivative":false,"issuer_cik":"0000792977","issuer_name":"AMAG PHARMACEUTICALS INC.","issuer_ticker":"AMAG","issuer_name_source":null,"issuer_url":"/issuer/0000792977","owner_cik":"0001537670","owner_name":"Holmes Scott A","owner_display_name":"Holmes Scott A","owner_url":"/insider/0001537670","role":"Officer (Chief Accounting Officer)","role_mark":"O","role_mark_label":"Officer (Chief Accounting Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Accounting Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":750.0,"shares_display":"750","price_per_share":15.54,"price_display":"15.54","price_state":"stated","total_value":11655.0,"total_display":"11,655.00","total_whole":"11,655","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-09-12","filed_date":"2012-09-13","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":25,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":3,"open_market":true},{"code":"S","label":"Open-market sale","n":22,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":25},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001114220","name":"KERYX BIOPHARMACEUTICALS INC","url":"/issuer/0001114220","role":"Officer (Chief Financial Officer)","n_filings":19,"first_seen":"2015-08-03","last_seen":"2018-11-16"},{"type":"issuer","type_label":"ISSUER","cik":"0000792977","name":"AMAG PHARMACEUTICALS INC.","url":"/issuer/0000792977","role":"Officer (SVP, Finance and Treasurer)","n_filings":4,"first_seen":"2012-09-13","last_seen":"2015-06-17"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001537670","retrieved_at":"2026-08-24T10:03:11+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}